EKSO - Ekso Bionics Holdings, Inc.
| Previous Close | 0.3795 |
| Open | 0.3650 |
| Bid | 0.3700 x 1400 |
| Ask | 0.3699 x 1200 |
| Day's Range | 0.3650 - 0.3764 |
| 52 Week Range | 0.3470 - 2.5500 |
| Volume | 255,420 |
| Avg. Volume | 1,000,161 |
| Market Cap | 32.012M |
| Beta (5Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1980 |
| Earnings Date | Feb 26, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.43 |
- GlobeNewswire
Ekso Bionics® to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2019 after the close of trading on Thursday, February 27, 2020. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers.
- GlobeNewswire
Post Acute Medical (PAM) Accelerates Adoption of Exoskeleton Rehabilitation with Three Additional EksoNR Devices from Ekso Bionics®
Post Acute Medical, LLC, (PAM), a system of inpatient rehabilitation hospitals, has acquired three additional EksoNR devices from Ekso Bionics (EKSO) to expand the availability of exoskeleton-assisted rehabilitation to seven of its facilities. Exoskeleton-assisted rehabilitation is now available at five PAM locations in Texas. The device is designed to help patients stand and walk during rehabilitation after a stroke or spinal cord injury.
- Simply Wall St.
Some Ekso Bionics Holdings (NASDAQ:EKSO) Shareholders Have Copped A 96% Share Price Wipe Out
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...
- GlobeNewswire
Ekso Bionics® Releases its Upgraded EksoPulse Platform, Advanced Cloud-Based Analytics for Robotic Exoskeleton-Assisted Rehabilitation
Ekso Bionics Holdings, Inc. (EKSO), a leading developer of robotic exoskeletons, today announced the worldwide launch of its upgraded EksoPulse platform, an innovative cloud-based information technology platform that measures and analyzes progress using the EksoNR robotic exoskeleton. The improved analytics system provides an easy-to-use dashboard to chart activity in rehabilitation sessions, enhancing the clinician, institutional, and patient experience of the most clinically used exoskeleton. The new EksoPulse platform technology uniquely allows physical therapists and physicians to track and personalize patient care with EksoNR.
- GlobeNewswire
Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2019 Financial Results; Company Achieves Record Fourth Quarter Revenue
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2019. Total revenue for the fourth quarter of 2019 is an estimated $3.7 million, reflecting year-over-year growth of 12.1% compared to total revenue of $3.3 million in the fourth quarter of 2018, and the highest quarterly revenue ever recorded by the Company. Estimated total revenue for the fourth quarter of 2019 includes approximately $3.2 million in medical revenue.
- Insider Monkey
Should You Buy Ekso Bionics Holdings, Inc. (EKSO)?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
- GlobeNewswire
Ekso Bionics Announces Closing of $5.0 Million Registered Direct Offering
Ekso Bionics Holdings, Inc. (EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the closing of its previously announced registered direct offering of 11,111,116 shares of its common stock and warrants to purchase up to 8,333,337 shares of its common stock, at a combined purchase price of $0.45 per share and associated warrant, for aggregate gross proceeds of approximately $5.0 million. The Company currently intends to use the net proceeds from the offering for general corporate purposes and working capital needs. The securities described above were offered and sold by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-218517), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on June 16, 2017.
- GlobeNewswire
Ekso Bionics® Expands Distribution of the EksoVest to Northern Europe
Ekso Bionics Holdings, Inc. (EKSO), a leading developer of exoskeletons for medical and industrial use, today announced it signed a distribution agreement with the largest Danish-owned distributor of building materials, BYGMA GRUPPEN A/S, to make the EksoVest available in Northern Europe. The Bygma Group is a solid Nordic group ranking among the top 100 companies in Denmark.
- GlobeNewswire
Ekso Bionics Announces $5.0 Million Registered Direct Offering
Ekso Bionics Holdings, Inc. (EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 11,111,116 shares of its common stock and warrants to purchase up to 8,333,337 shares of its common stock, at a combined purchase price of $0.45 per share and associated warrant, for aggregate gross proceeds of approximately $5.0 million. The Company currently intends to use the net proceeds from the offering for general corporate purposes and working capital needs. The securities described above are being offered and sold by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-218517), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on June 16, 2017.
- Simply Wall St.
Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- Thomson Reuters StreetEvents
Edited Transcript of EKSO earnings conference call or presentation 30-Oct-19 8:30pm GMT
Q3 2019 Ekso Bionics Holdings Inc Earnings Call
- GlobeNewswire
Ekso Bionics Reports Third Quarter 2019 Results
RICHMOND, Calif., Oct. 30, 2019 -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use,.
- GlobeNewswire
Ekso Bionics® to Report Third Quarter 2019 Financial Results on October 30, 2019
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2019 after the close of trading on Wednesday, October 30, 2019. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers.
- GuruFocus.com
Selling Tools to Miners: The Stocks That Can Profit on Biotech and Prosthetics
Determining which medical technology companies can increase their stock price Continue reading...
- Simply Wall St.
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO): What Does Its Beta Value Mean For Your Portfolio?
If you own shares in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) then it's worth thinking about how it contributes to...
- GlobeNewswire
Ekso Bionics to Present at the Cantor Fitzgerald Global Healthcare Conference on October 3, 2019
RICHMOND, Calif., Sept. 23, 2019 -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that Jack.
- Thomson Reuters StreetEvents
Edited Transcript of EKSO earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Ekso Bionics Holdings Inc Earnings Call
- GlobeNewswire
Ekso Bionics® Unveils the Next Generation Exoskeleton for Neurorehabilitation
Ekso Bionics Holdings, Inc. (EKSO), a leading developer of exoskeletons for medical and industrial use, today unveiled EksoNR, the next generation EksoGT— the most clinically used robotic exoskeleton. Developed for neurorehabilitation, EksoNR is an intuitive exoskeleton device that empowers patients recovering from stroke or other conditions to learn to walk again with a more natural gait. The device now includes new features and software enhancements to help physical therapists and patients get even more out of each rehabilitation session.
- Simply Wall St.
Do Institutions Own Shares In Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)?
If you want to know who really controls Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), then you'll have to look at the...
- GlobeNewswire
Ekso Bionics Reports Second Quarter 2019 Results
RICHMOND, Calif., Aug. 01, 2019 -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use,.
- GlobeNewswire
Ekso Bionics® to Report Second Quarter 2019 Financial Results on August 1, 2019
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2019 after the close of trading on Thursday, August 1, 2019. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers.
- GlobeNewswire
Ekso Bionics® Expands Its Medical Portfolio with Upper Body Exoskeleton for Rehabilitation
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced the expansion of its medical exoskeleton portfolio with an upper extremity rehabilitation device called EksoUE. The wearable upper body exoskeleton assists patients with a broad range of upper extremity impairment and aims to provide them with a wider range of motion and increased endurance for rehabilitation sessions of higher dose and intensity. Through a collaboration between Ekso Bionics and The Johns Hopkins University School of Medicine, the concept of EksoUE was beta-tested by the KATA Design Studio.
- Simply Wall St.
Introducing Ekso Bionics Holdings (NASDAQ:EKSO), The Stock That Tanked 88%
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
- Simply Wall St.
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO): Time For A Financial Health Check
While small-cap stocks, such as Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) with its market cap of US$97m, are popular...
- GlobeNewswire
Ekso Bionics Announces Closing of $10 Million Public Offering
Ekso Bionics Holdings, Inc. (EKSO) (the “Company,” “Ekso” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, announced today the closing of its previously announced underwritten public offering of 6,666,667 shares of its common stock and accompanying warrants to purchase 6,666,667 shares of its common stock, at a price to the public of $1.50 per share and accompanying warrant to purchase one share of common stock, for gross proceeds of $10.0 million before deducting underwriters’ discounts, commissions and estimated offering expenses. The securities described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-218517) relating to the public offering of such securities, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 6, 2017 and declared effective by the SEC on June 16, 2017.
